Engineered Enzyme Protects against Nerve Gas

English

A multidisciplinary team of scientists at the Weizmann Institute of Science succeeded in developing an enzyme that efficiently breaks down certain forms of nerve gas before damage to nerves and muscles can ensue. Their results were published in Nature Chemical Biology.
 
Agents in the gas disrupt the chemical messages sent between nerve and muscle cells, causing loss of muscle control and ultimately leading to death by suffocation. These substances interfere with the activity of acetylcholinesterase, the enzyme responsible for the breakdown of the chemical messenger – acetylcholine. As a result, acetylcholine continues to exert its effect, resulting in protracted muscle contractions throughout the body. Enzymes had been identified that are able to break down similar nerve agents, but these work inefficiently, making their use impractical.
 

Prof. Dan Tawfik of the Weizmann Institute’s Biological Chemistry Department and his group developed a special method to induce “natural selection” of enzymes in a test tube, enabling them to engineer tailor-made enzymes. Tawfik showed that this method can improve the efficiency of enzymes by factors of hundreds and even thousands.
 
The new mutant enzymes have been structurally analyzed by a team of scientists from the Structural Biology Department that included Profs. Joel Sussman and Israel Silman and research student Moshe Ben-David. Further experiments at USAMIRD labs have shown that when these enzymes were given preventively, they afforded animals near-complete protection against two types of nerve agents, even at relatively high exposures.
 
Prof. Dan Tawfik's research is supported by the Helen and Martin Kimmel Award for Innovative Investigation; the Willner Family Leadership Institute for the Weizmann Institute of Science; the Sassoon and Marjorie Peress Philanthropic Fund; Miel de Botton Aynsley, UK; Yossie Hollander, Israel; and Roberto and Renata Ruhman, Brazil. Prof. Tawfik is the incumbent of the Nella and Leon Benoziyo Professorial Chair.

Prof. Joel Sussman's research is supported by the Jean and Jula Goldwurm Memorial Foundation; the S. & J. Lurje Memorial Foundation; the Nalvyco Trust; Mr. Harold Chefitz, Livingston, NJ; Mr. and Mrs. Yossie Hollander, Israel; Nicolas and Elsa Neuman, Mexico; Dr. Ze'ev Rav-Noy, Los Angeles, CA; the Bruce and Rosalie N. Rosen Family Foundation; and Harry Sussman, Woodbury, NY. Prof. Joel Sussman is the incumbent of the Morton and Gladys Pickman Professorial Chair in Structural Biology.
Life Sciences
English

Springing Leaks

English
 
 
Normal mouse cells (l) and cells in which the MTCH2 gene is knocked out (r), after exposure to a cell suicide factor. Arrows point to a protein that initiates the cell suicide program, which is only released from mitochondria with functioning MTCH2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell suicide is a widespread phenomenon. When a cell is worn out, used up or irreparably damaged, or if changes in its DNA threaten to turn the cell cancerous, a special cellular mechanism is called upon to end things before trouble can ensue. But living cells have no access to ropes, knives or sleeping pills; they must resort to what’s at hand. A common method of cell suicide _ a process scientists refer to as apoptosis _ involves opening up the membranes of vital organelles called mitochondria and letting the proteins inside escape into the body of the cell. These normally harmless proteins team up with other proteins in the cell to disrupt its normal life processes and eventually destroy it.

Prof. Atan Gross of the Institute’s Biological Regulation Department investigates some of the steps in this complex process, specifically the proteins that deliver the suicide message to the mitochondria and initiate the necessary chain of events there. Many years ago, Gross started studying a protein called BID that’s involved in the pathway to suicide. Further research showed that this molecule must first undergo cleavage by another molecule before it can proceed with the suicide plan, and that the shortened version, called truncated BID (or tBID), activates another two proteins called BAX and BAK further down the line. The result of all this activity: The mitochondria develop a leaky outer membrane, which not only interferes with their main function – turning nutrients into the energy that powers the cell – but releases several different proteins into the body of the cell. Some of these proteins are among those directly implicated in the advanced stages of apoptosis, and several of the others may be involved as well.
(l-r) Liat Shachnai, Natalie Yivgi-Ohana, Prof. Atan Gross, Maria Maryanovich and Dr. Yehudit Zaltsman-Amir

A few years ago, Gross and his research team identified yet another player in this drama – a novel, previously uncharacterized protein sitting on the outer membrane of the mitochondria called mitochondrial carrier homolog 2 (or MTCH2).


What does this protein do? To find out, Gross and his team, including Dr. Yehudit Zaltsman-Amir and research student Liat Shachnai, began by creating mice embryos that lacked the gene for MTCH2. But these mice never made it to birth, a sign that the protein plays an important role in the body. Next, they created mice in which the gene could be neutralized (“knocked out”) in a specific organ at a specific time. The scientists then chose to knock out the gene in the liver.
 

Their results, which appeared in Nature Cell Biology, showed that MTCH2 acts as a receptor. From its post on the outside of the organelle, it attaches to a passing tBID molecule and transfers a signal to the inside of the mitochondrial membrane. The experiments showed that when this receptor was absent, the process stalled at some point after BID underwent cleavage. Most of the tBID failed to make it to the mitochondria, the suicide message was not passed on to BAX or BAK, and the membranes remained leak-free.


Gross and his team are continuing to investigate MTCH2, looking for other functions it may have. “For many proteins, apoptosis is the ‘night job.’ The ‘day job’ can be something completely different,” he says. “We think that MTCH2 may not even be a receptor in its day job; it is very similar to the mitochondrial carriers that transport various substrates across the mitochondrial membranes. We’re now working on finding out what it does when it’s not promoting cell suicide, and our preliminary studies hint at an intriguing connection to fat metabolism.”

Because apoptosis is vital to everything from embryonic development to everyday cell and tissue replacement to cancer prevention, the MTCH2 protein presents a promising target for drugs. Gross: “In cancer, cells fail to commit suicide; other diseases stem from too much or inappropriate apoptosis. We think we can find ways to manipulate the interaction between tBID and MTCH2 to address these problems.” Yeda, the technology transfer arm of the Weizmann Institute, has applied for patents on the protein, and research is already under way in Gross’s lab and collaborating groups to map out the physical interaction domains between the two proteins and develop new molecules that can block or enhance this interaction in disease processes.
 

Prof.  Atan Gross's research is supported by the Dr. Josef Cohn Minerva Center for Biomembrane Research; the Jeanne and Joseph Nissim Foundation for Life Sciences Research; the Victor Pastor Fund for Cellular Disease Research; and the Pearl Welinsky Merlo Foundation.

 
 
(l-r) Liat Shachnai, Natalie Yivgi-Ohana, Prof. Atan Gross, Maria Maryanovich and Dr. Yehudit Zaltsman-Amir
Life Sciences
English

A Method for Separating Biological Materials

English
Prof. Meir Wilchek
 
Prof. Meir Wilchek developed a method called affinity chromatography for separating biological materials, such as enzymes, antibodies, hormones and receptors. Prior to the advent of this method, many years of research were often needed to isolate a few milligrams of a substance.
 

Application

 
Since the 1970s, affinity chromatography has served as an important tool in all biotechnological fields, including genetic engineering and advanced fields of medicine and biology.
 
Prof. Meir Wilchek
Space & Physics
English

Biorecognition

English
Prof. Meir Wilchek
 
Since the 1960s, Prof. Meir Wilchek has studied "biorecognition”: the process in which biological substances "recognize" one another and form a bond. In particular, Wilcheck and his colleagues have focused on the strongest biological bond in nature, formed by the egg-white protein avidin and the vitamin biotin.
 

Application

 
Institute research on the avidin-biotin bond has provided the basis for thousands of applications in medicine, research and industry. Probes containing the avidin-biotin complex today constitute a $250 million a year market. Uses range from pollution control and blood clotting to diagnosis of genetic diseases, AIDS and various kinds of cancer.
 
Prof. Meir Wilchek
Space & Physics
English

Development of Synthetic Antigens

English
Prof. Ephraim Katzir
 
In the 1950s, Prof. Ephraim Katzir developed simple synthetic models, known as polyamino acids, that made it easier to study the properties of proteins.
 

Application

 
The study of the properties of polyamino acids, and above all of their immunological properties, enabled the development of synthetic antigens, which, among other things, led Weizmann scientists to develop the drug Copaxone, now used worldwide to treat multiple sclerosis.
 
Prof. Ephraim Katzir
Space & Physics
English

Immobilized Enzymes Used in the Pharmaceutical Industry

English
Prof. Ephraim Katzir d
 
In the 1960s, Prof. Ephraim Katzir developed a method for binding enzymes to a variety of insoluble carriers. Enzymes speed up many chemical processes, and the binding enables them to be reused time and again.
 

Application

 
Immobilized enzymes have become an important tool in the pharmaceutical industry. Among other things, they are used to manufacture penicillin and other antibiotics. They also form the basis of various processes in the food industry, for example in the production of fructose-enriched syrup.
 
Prof. Ephraim Katzir d
Space & Physics
English

Anti-Inflammatory Compounds

English
 Prof. David Wallach
 
For nearly two decades, Prof. David Wallach has studied receptors for the tumor necrosis factor, or TNF, an immune system substance that controls the damaging processes associated with inflammation. In these studies, Wallach identified two classes of proteins that block TNF activity.
 

Application

 
The proteins identified by Wallach are being used in clinical trials as anti-inflammatory compounds that may control rheumatoid arthritis and inflammatory bowel diseases (Crohn's disease and colitis).
 
 Prof. David Wallach
Space & Physics
English

What Makes Proteins Tick?

English
Three-dimensional structure of an enzyme, serum paraoxonase (PON1), which has been mutated in the lab of Prof. Dan Tawfik through directed evolution to endow the enzyme with new functions
 
 

 

Proteins. They’re the stuff of our muscles, nerves and organs. They’re the enzymes that control our body’s functions, the basic parts of the molecular machinery that keeps our cells alive, the molecules that transfer signals into cells and initiate gene copying so that more proteins can be made. Each of the hundreds of thousands of different proteins in our bodies is produced as a long chain of amino acids that folds up into a unique shape.

Some of these – those that maintain our body’s structure, for instance – keep this shape throughout; but others shift, bend and stretch as they work. Uncovering the complex interplay between form and function, between one protein and another, between genes and the proteins they encode, is not only important for learning how the body works; it’s crucial for understanding many types of disease, as well as the body’s response to disease-causing pathogens.

Institute scientists employ a wide variety of approaches to researching proteins – from solving the structure of crystallized proteins to creating computer simulations of protein dynamics.

In the Faculty of Biochemistry, Prof. Gideon Schreiber examines interactions between proteins. His studies of interferon – a part of the body’s response to viral pathogens – are revealing how a single protein can transmit different signals depending on how it binds to cell wall receptors, and this information may lead to improved interferon-based drugs. Prof. Dan Tawfik investigates how proteins evolve. His methods for directing their evolution in the lab enable him to trace the evolution of new structures and functions, and to generate proteins with therapeutic potential. Prof. Rivka Dikstein looks at the mechanisms that control the types and amounts of proteins produced in each cell. She recently discovered a mechanism, shared by 5% of the genes, that coordinates the two major stages of protein production: gene transcription and its translation into protein.
 
 
Profs. Dan Tawfik, Rivka Dikstein and Gideon Schreiber
 
 

 

Prof. Rivka Dikstein’s research is supported by the Yeda-Sela Center for Basic Research; and the Pearl Welinsky Merlo Foundation. Prof. Dikstein is the incumbent of the Ruth and Leonard Simon Chair of Cancer Research.

Prof. Gideon Schreiber’s research is supported by the Clore Center for Biological Physics; and the Helen and Milton A. Kimmelman Center for Biomolecular Structure and Assembly.

Prof. Dan Tawfik’s research is supported by the J&R Center for Scientific Research; the Willner Family Leadership Institute for the Weizmann Institute of Science; the Wolgin Prize for Scientific Excellence; the Sassoon and Marjorie Peress Philanthropic Fund; Miel de Botton Aynsley, UK; Samy Cohn, Brazil; Mario Fleck, Brazil; Yossie Hollander, Israel; David Rosenberg, Houston, TX; Charles Rothschild, Brazil; and Roberto and Renata Ruhman, Brazil. Prof. Tawfik is the incumbent of the Nella and Leon Benoziyo Professorial Chair.

 
 
Three-dimensional structure of an enzyme, serum paraoxonase (PON1), which has been mutated in the lab of Prof. Dan Tawfik through directed evolution to endow the enzyme with new functions
Life Sciences
English

It All Depends

English
Prof. Zvi Livneh. Cell decisions: to fix or not to fix?
 
 

 

Are they good or are they bad? Genetic mutations, that is. The answer, like the answers to so many other questions in life is: It all depends. What it depends on is context, and that context has to do with Darwin and the ways in which cancer inhabits and inhibits the lives of our planet's beings.
 
It all starts with our day-to-day existence, when the DNA in living cells is exposed to a plethora of environmental effects ­ solar rays, chemical materials, the by-products of the metabolic process within the cells themselves, etc. Simply stated: Our DNA becomes all stressed out.

These stressful influences may consequently damage DNA, and are expressed in change, breakdown, and replacement of the genetic "letters" which comprise our genetically-encoded information. (DNA is built from millions of these genetic letters.) Damaged data leads to the creation of defective proteins, which may in turn alter the correct operation of the cell. Under certain circumstances, this can even lead to cell death.

Here's the lowdown on understanding how mutation works.
 
"Bad" mutations may activate cancer-causing genes, or "switch off" cancer-resistant genes; without the protection of resistance, there's a possibility of the development of cancerous growth. Other negative mutations are liable to jumpstart the processes which cause the appearance of other diseases.
 
On the other hand, "good" mutations form the steps upon which life ascends the evolutionary ladder. In fact, without mutation, evolution is impossible.
 
We're all familiar with that first evolutionary revolutionary, Darwin. While he didn't have access to the sophisticated research techniques of today, Darwin's work constituted a precursor to the field of genetics.
 
A century later, scientific research is delving into the wide genetic differences by which natural selection acts. Darwin certainly would have been intrigued to learn that selection is based on the accumulation of nonfatal mutations in hereditary DNA material within the nuclei of all living creatures. This process sometimes triggers an improvement in the survivability of living creatures.
 
That's where Prof. Zvi Livneh and his research students, Nina Reuven and Guy Tomer, of the Institute's Biological Chemistry Department, come into the evolutionary picture. With survivability the issue, the Weizmann Institute team is asking this question: How do you prevent and reduce, to whatever extent possible, the damage of the bad mutations on one hand, while on the other, preserve what is most beneficial about the evolutionary process?
 
What we do know is that the living, breathing world has its own built-in, sophisticated mechanisms that allow cells to repair defective DNA. However, these mechanisms aren't always perfect; they sometimes undertake their work with a certain degree of "negligence." This opens the possibility for other mutations, only some of which may be considered beneficial ones.
 
Mutations are incorrect coding instructions, formed when the replication machinery duplicates the DNA regions containing the unrepaired lesions. It was originally thought that replication stops when encountering damaged DNA, and that the process would continue only with the assistance of "helping proteins."
 
What Livneh and his team discovered is that the enzyme polymerase, which replicates the DNA, "didn't stop at the red light" when it came upon the damage ­ not even in the absence of the helping proteins.
 
So why are the helping proteins required at all?
 
First, the helpers make the replication of DNA damage go faster. But what Livneh and team found is yet another reason: The choice of the polymerase to replicate the damaged region either by itself, or with the assistance of the helping proteins, is a life or death decision.
 
Without the presence of helping proteins, the polymerase ignores DNA damage, leaving blank spaces of one or two letters in the DNA's genetic continuity. If DNA is like a book containing words made of letters that appear in triplet form, removing one or two of them sends a whole different message. For example, if you have the sentence "Dad did cry" and you remove "D" from "Dad," the message is read as "add idc ry." The message is clearly set askew.
 
This leads to the creation of shortened proteins that are liable to hasten the cell's death. When polymerase encounters damage and continues its action in the presence of helping proteins, it fills in the blanks created in the genetic continuity with random genetic letters. While this still leads to the creation of a mutation, it is a mild type and the mutant proteins can work, if only partially. In any event, they do not usually bring about the death of the cell. In fact, they may act like some of us do when we're under stress: We perform better. On occasion, the mutation can actually improve the protein.
 
Livneh: "We knew this before, but we didn't know the rationale for it. If the helping proteins aren't there, the replication machine is making disastrous mistakes."
 
Prof. Livneh's discovery: reconstituting the entire mutagenic process in a test tube by taking components from billions of living cells. Put them to work outside the cells.
Sit back a few minutes while the entire filling-in process happens in a matter of minutes.
 
What does Livneh's research have to do with life in the 21st century? Plenty. It's important to note that one way bacteria acquire resistance to antibiotics is due to mutation. Beneficially, one of the potential, long-range applications of Livneh's work is the possibility that some day, we may be able to counteract this scary news: We're running out of antibiotics that kill bacteria.
 
Under most circumstances, it is clear that mutations created as a reaction to conditions of stress, improve the ability of bacteria to survive these conditions. Prof. Livneh's research is likely to broaden the boundaries of our knowledge regarding the ways in which living creatures are able to adapt to environmental conditions through evolution, good or bad.
 
It all depends.
 

Many causes of DNA damage. illustration: Mutations

 
Life Sciences
English

Picking Up Speed

English

Prof. Dan Tawfik. The mutations that drive evolution

Charles Darwin realized that it's not money but mutations that make the world go round. Mutations drive evolution: They alter gene sequences, tweaking the function of their protein products and assuring the adaptability of organisms to ever-changing environments.

In nature, proteins are able to evolve new functions surprisingly rapidly and efficiently. In contrast, scientists who try to evolve proteins in the test tube do not fare as well. One snag lies in the precise 3-D structures proteins must get folded into before they can function. These structures are very fragile, so introducing even a minor mutation can undermine the protein’s stability, causing it to misfold. To protect the organism, many such mutations – including those with the potential to endow proteins with new functions – are purged. “Like throwing the baby out with the bath water, the future potential for adaptation is also destroyed, and this severely limits the rate of protein evolution,” says Prof. Dan Tawfik of the Weizmann Institute’s Biological Chemistry Department.

Scientists are keen on revealing how nature deals with these mutations because the ability to evolve proteins in the laboratory – so-called “directed evolution” – provides a powerful means for engineering tailor-made enzymes (proteins that speed up chemical reactions) with novel properties for a range of industrial, biotechnological and medical applications.

It turns out that in living cells these trouble-prone proteins are accompanied by chaperones – protein babysitters that help newly-synthesized proteins fold into the correct 3-D structures and later save them when they get into hot water – literally. When a cell undergoes such environmental stress as exposure to high temperatures, causing proteins to misfold, high numbers of chaperones are induced to rescue the misfolded proteins and help the cell survive the so-called heat shock.

Tawfik wondered whether these same chaperones could perform a similar function in the lab: keeping mutated proteins out of trouble and thus accelerating directed protein evolution. To find out, postdoctoral fellow Dr. Nobuhiko Tokuriki carried out directed evolution experiments, introducing random mutations in selected enzymes, both in the presence and absence of large amounts of a chaperone from the bacterium E. coli, called GroEL/GroES.

In a research article recently published in Nature and featured in its “Making the Paper” section, Tawfik and Tokuriki showed that the chaperones seemed to buffer the effects of many mutations and, in doing so, were able to save about one-third of the mutated proteins that would otherwise have perished. This, in turn, enabled proteins to acquire twice as many mutations, promoting genetic diversity and accelerating the rate at which they acquired new functions through generations of evolution. What’s more, the evolved proteins that had chaperone help were, on average, 10 times more active and more specifically adapted to their tasks than their chaperoneless cousins.

Tawfik: “These results are quite striking. Although the scientific community suspected that chaperones could play a role in salvaging mutated proteins, there was no systematic evidence to support the idea, let alone the remarkably high extent of their rescue capabilities.”

Two hundred years after Darwin’s birth, this work adds another detail to the evolutionary picture, providing direct evidence that protein stability is, indeed, a major constraint in protein evolution and that buffering mechanisms such as chaperones are key in alleviating such constraints.

In light of this research, chaperones will almost certainly be used routinely by those trying to produce more powerful enzymes for biotechnical applications. Tawfik: “Whether evolving in nature or the lab, if you’re not fast you’ll never make it to the finish line.”

Prof. Dan Tawfik’s research is supported by the J&R Center for Scientific Research; the Willner Family Leadership Institute for the Weizmann Institute of Science; the Sassoon and Marjorie Peress Philanthropic Fund; the Jack Wolgin Prize for Scientific Excellence; Miel de Botton Aynsley, UK; Mario Fleck, Brazil; Mr. and Mrs. Yossie Hollander, Israel; Roberto and Renata Ruhman, Brazil; David Rosenberg, Houston, TX; Charles Rothschild, Brazil; and Rowland Schaefer, New York, NY.

 

A Welcome Surprise

 
Nobuhiko Tokuriki. The only Japanese student

 

 

 

 

 

 

 

 

Nobuhiko (Nobu) Tokuriki became interested in science at a young age – especially evolution. During his undergraduate studies, he learned of directed evolution and knew that was what he wanted to research. Impressed by Tawfik’s work, Nobu contacted him at the University of Cambridge, UK, and asked if he could conduct his postdoctoral studies in Tawfik’s lab. Tawfik agreed, although there was one catch – he had already moved back to Israel to conduct research at the Weizmann Institute. “I had hardly heard of Israel, let alone the Weizmann Institute, before I contacted Danny, but I thought, why not, it could be an interesting experience,” says Nobu. And he was not disappointed: “It was certainly an amazing experience to work in such a fine institute, with many great scientists, lots of activity and a wonderful atmosphere. Also, being the only Japanese student at that time was an experience in itself: Apart from comparing various cultural differences, I also had the honor of being asked to meet a Japanese ambassador, Japanese diplomats and various other visitors from Japan.”

 

Since then, Nobu has come full circle and is continuing his research at the University of Cambridge, UK.

 
Prof. Dan Tawfik. Saving mutations
Life Sciences
English

Pages